Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3Other hematologic neoplasm 1

Conditions

Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × cobomarsen × Clear all
NCT03713320 2022-04-08

SOLAR

miRagen Therapeutics, Inc.

Phase 2 Terminated
37 enrolled 23 charts
DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02580552 2020-11-23

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

miRagen Therapeutics, Inc.

Phase 1 Completed
66 enrolled
DermatologicLymphoidOther hematologic neoplasm

Mycosis Fungoides, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03837457 2020-11-19

PRISM

miRagen Therapeutics, Inc.

Phase 2 Terminated
8 enrolled
DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡